The US Food and Drug Administration (FDA) has approved AbbVie’s Duopa (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson’s disease. Duopa is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a procedurally-placed tube.

Duopa was approved by the FDA as an orphan drug, a designation granted to products intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the US.

Carbidopa and levodopa enteral suspension is currently approved in 41 countries and is marketed by AbbVie as Duodopa outside the United States.

Source: AbbVie